“50 Years of Hematopoietic Stem Cell Transplantation”

“50 Years of Hematopoietic Stem Cell Transplantation”

We were honored to hear from Professor Xiaojun Huang of Peking University People’s Hospital and the Peking University Institute of Hematology, who shared a comprehensive reflection on the global evolution of hematopoietic stem cell transplantation (HSCT). From Dr. Edward Donnall Thomas' foundational work to the creation of the Beijing Protocol, Professor Huang spotlighted how China’s innovations—including non–T-cell-depleted haploidentical transplantation—are transforming clinical practice worldwide.
CSCO Guidelines Conference | Academician Jinming Yu: From the “Jinan Miracle” in Radiation Therapy to Advancing Immunotherapy and International Collaboration

CSCO Guidelines Conference | Academician Jinming Yu: From the “Jinan Miracle” in Radiation Therapy to Advancing Immunotherapy and International Collaboration

The 2025 CSCO Guidelines Conference, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, was successfully held in Jinan, April 18–19, 2025. Leading experts from across the country gathered once again to exchange cutting-edge research, discuss clinical hot topics, and witness the release of updated CSCO guidelines. Oncology Frontier had the honor of interviewing the conference chair, CSCO Council President, and Academician Jinming Yu of Shandong Cancer Hospital, who shared insights into proton therapy, combined radiotherapy and immunotherapy, and CSCO’s path toward deeper international collaboration.
CUDA Yanqi Lake Meeting | Professor Liqun Zhou: Advancing the Diagnostic Frontier to Improve Survival in Chinese Prostate Cancer Patients

CUDA Yanqi Lake Meeting | Professor Liqun Zhou: Advancing the Diagnostic Frontier to Improve Survival in Chinese Prostate Cancer Patients

In recent years, the incidence of prostate cancer in China has continued to rise, creating an urgent need to improve diagnostic and treatment strategies tailored to this growing patient population. At the 5th Annual CUDA Yanqi Lake Meeting (2025), hosted by the Chinese Urological Doctor Association, UroStream invited Professor Liqun Zhou, Institute of Urology, Peking University, to discuss the importance of early screening, optimized diagnostic approaches, and advances in neoadjuvant therapy. His insights point toward practical steps for enhancing the survival and quality of life of prostate cancer patients in China.